This protocol details the process of quantifying newly synthesized N-Myc and global proteins in SK-N-BE (2) neuroblastoma cells, a model for aggressive neuroblastoma with MYCN amplification, to assess the efficacy of drugs1 or small molecules in inhibiting protein synthesis as a potential therapeutic strategy.2 The gene discussed is MYCN; the disease is neuroblastoma.